Stephen L. Rawlings

Array ( [id] => 14883513 [patent_doc_number] => 10421783 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-09-24 [patent_title] => Prostate-specific membrane antigen (PSMA) targeting peptides [patent_app_type] => utility [patent_app_number] => 15/437248 [patent_app_country] => US [patent_app_date] => 2017-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 10084 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15437248 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11649195 [patent_doc_number] => 20170145097 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-25 [patent_title] => 'HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR CD22' [patent_app_type] => utility [patent_app_number] => 15/424238 [patent_app_country] => US [patent_app_date] => 2017-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 23349 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15424238 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16125993 [patent_doc_number] => 10696738 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-30 [patent_title] => Anti-serum albumin binding variants [patent_app_type] => utility [patent_app_number] => 15/363223 [patent_app_country] => US [patent_app_date] => 2017-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 2 [patent_no_of_words] => 17388 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15363223 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16321308 [patent_doc_number] => 10781264 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-22 [patent_title] => PSMA and CD3 bispecific T cell engaging antibody constructs [patent_app_type] => utility [patent_app_number] => 15/422661 [patent_app_country] => US [patent_app_date] => 2017-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 18 [patent_no_of_words] => 52425 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 187 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15422661 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11821866 [patent_doc_number] => 20170210803 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-27 [patent_title] => 'TREATMENT OF CANCER WITH COMBINATIONS OF IMMUNOREGULATORY AGENTS' [patent_app_type] => utility [patent_app_number] => 15/411623 [patent_app_country] => US [patent_app_date] => 2017-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 17567 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15411623 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11668511 [patent_doc_number] => 20170157231 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-08 [patent_title] => 'Therapeutic Cancer Vaccine' [patent_app_type] => utility [patent_app_number] => 15/410842 [patent_app_country] => US [patent_app_date] => 2017-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 7379 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15410842 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11743979 [patent_doc_number] => 20170198051 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-13 [patent_title] => 'MULTIVALENT AND MULTISPECIFIC OX40-BINDING FUSION PROTEINS' [patent_app_type] => utility [patent_app_number] => 15/404167 [patent_app_country] => US [patent_app_date] => 2017-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 21168 [patent_no_of_claims] => 47 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15404167 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12983668 [patent_doc_number] => 20170343550 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-30 [patent_title] => NOVEL ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 15/402081 [patent_app_country] => US [patent_app_date] => 2017-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27369 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15402081 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11979333 [patent_doc_number] => 20170283487 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-05 [patent_title] => 'IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS' [patent_app_type] => utility [patent_app_number] => 15/400618 [patent_app_country] => US [patent_app_date] => 2017-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 60719 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15400618 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11742885 [patent_doc_number] => 20170196957 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-13 [patent_title] => 'RECOMBINANT T CELL RECEPTOR LIGAND COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CANCER' [patent_app_type] => utility [patent_app_number] => 15/400587 [patent_app_country] => US [patent_app_date] => 2017-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 13155 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15400587 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11542654 [patent_doc_number] => 20170096480 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-06 [patent_title] => 'ANTIBODY VARIANTS' [patent_app_type] => utility [patent_app_number] => 15/384962 [patent_app_country] => US [patent_app_date] => 2016-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 24670 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15384962 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11704632 [patent_doc_number] => 20170173132 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-22 [patent_title] => 'NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST BREAST CANCER AND OTHER CANCERS' [patent_app_type] => utility [patent_app_number] => 15/384963 [patent_app_country] => US [patent_app_date] => 2016-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 42251 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15384963 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11554232 [patent_doc_number] => 20170100478 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-13 [patent_title] => 'ANTI-ANGIOGENESIS THERAPY FOR THE TREATMENT OF BREAST CANCER' [patent_app_type] => utility [patent_app_number] => 15/385602 [patent_app_country] => US [patent_app_date] => 2016-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 27318 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15385602 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11706266 [patent_doc_number] => 20170174766 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-22 [patent_title] => 'ANTIBODY FORMULATION' [patent_app_type] => utility [patent_app_number] => 15/375239 [patent_app_country] => US [patent_app_date] => 2016-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 96814 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15375239 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13165689 [patent_doc_number] => 10098937 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-10-16 [patent_title] => Peptides and combination of peptides for use in immunotherapy against various cancers [patent_app_type] => utility [patent_app_number] => 15/375030 [patent_app_country] => US [patent_app_date] => 2016-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 38 [patent_no_of_words] => 53916 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 172 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15375030 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13091207 [patent_doc_number] => 10064928 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-09-04 [patent_title] => Peptides and combination of peptides for use in immunotherapy against CLL and other cancers [patent_app_type] => utility [patent_app_number] => 15/374054 [patent_app_country] => US [patent_app_date] => 2016-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 27 [patent_no_of_words] => 42612 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 140 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15374054 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13165691 [patent_doc_number] => 10098938 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-10-16 [patent_title] => Peptides and combination of peptides for use in immunotherapy against various cancers [patent_app_type] => utility [patent_app_number] => 15/375047 [patent_app_country] => US [patent_app_date] => 2016-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 38 [patent_no_of_words] => 54097 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 144 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15375047 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14258957 [patent_doc_number] => 10279022 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-05-07 [patent_title] => Peptides and combination of peptides for use in immunotherapy against various cancers [patent_app_type] => utility [patent_app_number] => 15/375051 [patent_app_country] => US [patent_app_date] => 2016-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 38 [patent_no_of_words] => 54082 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 130 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15375051 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13263321 [patent_doc_number] => 10143730 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-12-04 [patent_title] => Peptides and combination of peptides for use in immunotherapy against various cancers [patent_app_type] => utility [patent_app_number] => 15/374452 [patent_app_country] => US [patent_app_date] => 2016-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 38 [patent_no_of_words] => 54190 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 164 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15374452 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11689623 [patent_doc_number] => 20170165338 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-15 [patent_title] => 'NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS' [patent_app_type] => utility [patent_app_number] => 15/375017 [patent_app_country] => US [patent_app_date] => 2016-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 34 [patent_no_of_words] => 55644 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15375017 [rel_patent_id] =>[rel_patent_doc_number] =>)